Bardoxolone methyl

( DrugBank: Bardoxolone methyl, Bardoxolone / KEGG DRUG: Bardoxolone methyl, Bardoxolone )


5 diseases
IDDisease name (Link within this page)Number of trials
67Polycystic kidney disease13
84Sarcoidosis1
85Idiopathic interstitial pneumonia1
IDDisease name (Link within this page)Number of trials
86Pulmonary arterial hypertension9
218Alport syndrome8

67. Polycystic kidney disease


Clinical trials : 233Drugs : 188 - (DrugBank : 54) / Drug target genes : 60 - Drug target pathways : 165 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

84. Sarcoidosis


Clinical trials : 175Drugs : 189 - (DrugBank : 80) / Drug target genes : 74 - Drug target pathways : 177 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

85. Idiopathic interstitial pneumonia


Clinical trials : 723Drugs : 411 - (DrugBank : 126) / Drug target genes : 104 - Drug target pathways : 212 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

86. Pulmonary arterial hypertension


Clinical trials : 1,288Drugs : 565 - (DrugBank : 126) / Drug target genes : 81 - Drug target pathways : 191 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

218. Alport syndrome


Clinical trials : 41Drugs : 32 - (DrugBank : 19) / Drug target genes : 8 - Drug target pathways : 44 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries